Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study
- PMID: 35907102
- DOI: 10.1007/s10067-022-06302-z
Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study
Abstract
Background: Autoimmune diseases, including systemic lupus erythematosus, have been associated with a substantial risk of cardiovascular morbidity and mortality. However, data on the long-term risk of incident heart failure and other adverse cardiovascular outcomes among patients diagnosed with cutaneous lupus erythematosus (CLE) are limited.
Methods: In this cohort study, all patients ≥ 18 years with newly diagnosed CLE between 1996 and 2018 were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidity with individuals without CLE. Incident adverse cardiovascular outcomes, including heart failure, were compared between the matched groups, overall, and according to sex.
Results: Of 2085 patients diagnosed with CLE, 2062 patients were matched with 8248 control subjects from the Danish background population (median age 50 years [25th-75th percentile: 37-62 years]; 22.3% men). The median follow-up was 6.2 years. The 10-year cumulative incidences and adjusted hazard ratios (HR) of outcomes were as follows: heart failure: 3.29% (95% CI, 2.42-4.36%) for CLE patients versus 2.59% (2.20-3.02%) for the background population, HR 1.67 (95% CI, 1.24-2.24); atrial fibrillation or flutter: 5.15% (3.99-6.52%) versus 3.84% (3.37-4.36%), HR 1.40 (1.09-1.80); the composite of ICD implantation, ventricular arrhythmia, or cardiac arrest: 0.72% (0.34-1.40%) versus 0.44% (0.29-0.64%), HR 1.71 (0.85-3.45); the composite of pacemaker implantation, atrioventricular block, or sinoatrial dysfunction: 0.91% (0.48-1.59%) versus 0.54% (0.37-0.76%), HR 1.32 (0.72-2.41); myocardial infarction: 3.05% (2.18-4.15%) versus 1.59% (1.29-1.93%), HR 2.15 (1.53-3.00); ischemic stroke: 3.25% (2.38-4.32%) versus 2.50% (2.13-2.93%), HR 1.56 (1.16-2.10); and venous thromboembolism: 2.74% (1.94-3.75%) versus 2.05% (1.71-2.44%), HR 1.60 (1.16-2.21). Sex did not modify the association between CLE and adverse cardiovascular outcomes (Pinteraction ≥ 0.12 for all outcomes).
Conclusions: Patients with CLE had a higher associated risk of adverse cardiovascular outcomes compared with the background population, irrespective of sex. Key Points • Findings: In this nationwide cohort study, including 2062 patients with cutaneous lupus erythematosus and 8248 matched controls, cutaneous lupus erythematosus was associated with an increased long-term risk of heart failure, cardiac arrhythmias, and thromboembolic events, irrespective of sex.
Keywords: Cardiac arrhythmias; Cutaneous lupus erythematosus; Heart failure; Thromboembolism.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Similar articles
-
Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.Lupus. 2017 Jan;26(1):48-53. doi: 10.1177/0961203316651739. Epub 2016 May 27. Lupus. 2017. PMID: 27235406
-
Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: A Danish nationwide cohort study.Lupus. 2021 Apr;30(5):752-761. doi: 10.1177/0961203321990106. Epub 2021 Jan 26. Lupus. 2021. PMID: 33497306
-
Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Cutaneous Lupus Erythematosus: A Population-Based Cohort Study.Arthritis Care Res (Hoboken). 2016 Nov;68(11):1664-1670. doi: 10.1002/acr.22892. Arthritis Care Res (Hoboken). 2016. PMID: 27015109 Free PMC article.
-
Interventions for cutaneous disease in systemic lupus erythematosus.Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. Cochrane Database Syst Rev. 2021. PMID: 33687069 Free PMC article.
-
Cutaneous lupus erythematosus and cardiovascular disease: current knowledge and insights into pathogenesis.Clin Rheumatol. 2021 Feb;40(2):491-499. doi: 10.1007/s10067-020-05257-3. Epub 2020 Jul 5. Clin Rheumatol. 2021. PMID: 32623651 Review.
Cited by
-
Polyautoimmunity in patients with cutaneous lupus erythematosus: A nationwide sex- and age-matched cohort study from Denmark.JAAD Int. 2023 Aug 25;13:126-133. doi: 10.1016/j.jdin.2023.07.018. eCollection 2023 Dec. JAAD Int. 2023. PMID: 37808964 Free PMC article.
-
Cardiovascular issues in rheumatic diseases.Clin Rheumatol. 2023 Oct;42(10):2535-2539. doi: 10.1007/s10067-023-06656-y. Epub 2023 Jun 3. Clin Rheumatol. 2023. PMID: 37269421 Review.
-
Association between systemic lupus erythematosus and cardiovascular health based on genetic data.Clin Rheumatol. 2025 Jun;44(6):2277-2285. doi: 10.1007/s10067-025-07396-x. Epub 2025 May 3. Clin Rheumatol. 2025. PMID: 40317457
-
Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus.JAMA Dermatol. 2025 Feb 1;161(2):175-182. doi: 10.1001/jamadermatol.2024.4991. JAMA Dermatol. 2025. PMID: 39630434
-
Modern therapy of patients with lupus erythematosus must include appropriate management of their heightened rates of atherosclerotic cardiovascular events: a literature update.Lupus Sci Med. 2025 Apr 8;12(1):e001160. doi: 10.1136/lupus-2024-001160. Lupus Sci Med. 2025. PMID: 40204295 Free PMC article. Review.
References
-
- Filotico R, Mastrandrea V (2018) Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol 153(2):216–29. https://doi.org/10.23736/s0392-0488.18.05929-1 - DOI - PubMed
-
- Wenzel J (2019) Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol 15(9):519–532. https://doi.org/10.1038/s41584-019-0272-0 - DOI - PubMed
-
- Kuhn A, Sticherling M, Bonsmann G (2007) Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 5(12):1124–1137. https://doi.org/10.1111/j.1610-0387.2007.06554.x - DOI - PubMed
-
- England BR, Thiele GM, Anderson DR, Mikuls TR (2018) Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. Bmj 361:k1036. https://doi.org/10.1136/bmj.k1036 - DOI - PubMed - PMC
-
- Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Jensen GV, Torp-Pedersen C et al (2013) Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death–a Danish nationwide cohort study. PLoS ONE 8(2):e56944. https://doi.org/10.1371/journal.pone.0056944 - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources
Medical